SCTX Stock Forecast: Scribe Therapeutics, Inc. Price Predictions for 2026-2027
The 3 Wall Street analysts covering Scribe Therapeutics, Inc. hold a median 12-month price target of $50 — +46.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
SCTX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Scribe Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (51): Smaller than most of the companies we track.
Issuance (1): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
SCTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SCTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +46.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Aug 2026 | Guggenheim | Initiates | Buy | $50 |
| 18 Aug 2026 | Leerink Partners | Initiates | Outperform | $37 |
| 18 Aug 2026 | Wells Fargo | Initiates | Overweight | $60 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SCTX appears on the weeks it earns a place.
SCTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Scribe Therapeutics, Inc. (SCTX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 15.2×
- Price / book
- —
- EV / EBITDA
- −6.7×
Cheaper than 11% of US stocks
Cheaper than 80% of US stocks
- Revenue growth (YoY)
- −87.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −556.5%
- Net margin
- −98.5%
Higher than 2% of US stocks
Higher than 7% of US stocks
Higher than 6% of US stocks
- Return on equity
- 15.2%
- Return on assets
- −27.9%
- Dividend yield
- —
Higher than 74% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
SCTX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Scribe Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about SCTX stock
What is the SCTX stock price forecast for 2026-2027?
The 3 Wall Street analysts covering Scribe Therapeutics, Inc. have a median 12-month price target of $50, with estimates ranging from $37 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SCTX stock a buy right now?
Of the 3 analysts covering Scribe Therapeutics, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Scribe Therapeutics, Inc. 1 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SCTX?
As at 22 Aug 2026, Scribe Therapeutics, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (51 of 100).
Will SCTX stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts implies +46.5% from the last close, and Ticker Nerd's factor model ranks Scribe Therapeutics, Inc. 1 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SCTX stock forecast for 2030?
No analyst covering Scribe Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SCTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $37 to $60 over the next 12 months.
What does Scribe Therapeutics, Inc. do?
Scribe Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of in vivo CRISPR-based genetic medicines for highly prevalent cardiometabolic diseases.
About Scribe Therapeutics, Inc.
Scribe Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of in vivo CRISPR-based genetic medicines for highly prevalent cardiometabolic diseases. The company engineers purpose-built gene editing and epigenetic silencing therapies designed to modify disease-driving biology directly in the body, with an emphasis on durable intervention without permanent changes to DNA when possible. Its lead program, STX-1150, is a liver-targeted therapy that uses ELXR epigenetic silencing technology to repress the PCSK9 gene, aiming to durably lower LDL cholesterol by modulating a well-validated cardiovascular risk factor. Additional pipeline candidates, including programs targeting Lp(a) and triglycerides via the LPA and APOC3 genes, extend its focus across key drivers of atherosclerotic cardiovascular disease. Scribe Therapeutics applies its proprietary CRISPR by Design platform, incorporating advanced molecular engineering and validation methods to enhance specificity and therapeutic precision. Founded in 2017 and headquartered in Alameda, California, Scribe Therapeutics operates today at the intersection of gene editing and cardiometabolic medicine, serving the broader genetic medicine and healthcare sectors.
CEO Dr. Benjamin L. Oakes Ph.D. · 89 employees · United States · https://www.scribetx.com